Telehealth-delivered HealthcaRe to ImproVe Care
THRIVE
1 other identifier
observational
1,580
1 country
1
Brief Summary
Objective 1: Evaluate patients' satisfaction with their telehealth care and determine factors associated with satisfaction. Objective 2: Deploy PROs and patient self-assessment tools, specifically a patient-facing instructional in-app tool that instructs RA patients how to perform self-assessment examinations to observe and report the number of tender and swollen joint counts.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 27, 2022
CompletedFirst Posted
Study publicly available on registry
August 2, 2022
CompletedStudy Start
First participant enrolled
January 3, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2025
CompletedAugust 6, 2024
August 1, 2024
1.9 years
July 27, 2022
August 5, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Correlation between patient joint count and provider joint count
The investigators will examine and compare the patient and rheumatology provider's tender and swollen joint count summed scores and Pearson and Spearman's correlation coefficient (if the data is non-normally distributed). The investigators will also calculate a typical Clinical Disease Index (CDAI) for RA which is a composite score of TJC28 + SJC28 + Patient Global + Provider Global and correlate with the patient \[p\] CDAI (\[p\]TJC28 + \[p\]SJC28 + Patient Global + Provider Global). Disease remission for RA is denoted by a CDAI composite score of less than or equal to 2.8 while high RA disease activity is denoted by a CDAI score of 22 or greater. The investigators will also compute weighted kappa statistics, comparing the 4x4 table of remission, low moderate, and high disease activity categories, using the traditional CDAI cut points (2.8, 10, and 22).
Immediately after the intervention
Study Arms (2)
Objective 1: Telehealth Visit
Any rheumatology patient, seen and treated by a participating physician, who is 19 years and older, with the target condition(s) of interest, and is already scheduled for a telehealth visit.
Objective 2: ArthritisPower App
Patients diagnosed with Rheumatoid Arthritis who already have a pre-scheduled in-office visit.
Interventions
Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
Eligibility Criteria
Adults with Rheumatoid Arthritis seen in a Rheumatology Clinic.
You may qualify if:
- Must be 19 years or older.
- Must have a prior diagnosis of Rheumatoid Arthritis.
- Must be able to read and write in English or Spanish.
You may not qualify if:
- Younger than 19 years of age
- Does not have a prior diagnosis of Rheumatoid Arthritis.
- Unable to read and write in English or Spanish
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Attune Health Research, Inc.lead
- Rheumatology Research Foundationcollaborator
Study Sites (1)
Attune Health Research Inc
Beverly Hills, California, 90211, United States
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2022
First Posted
August 2, 2022
Study Start
January 3, 2023
Primary Completion
December 1, 2024
Study Completion
April 1, 2025
Last Updated
August 6, 2024
Record last verified: 2024-08